S_ary ADEPT is an antibody-based targeting strategy for the treatment of cancer. We have developed shown to localise specifically to established LoVo tumour xenografts growing in nude mice and optimal tumour-normal tissue ratios were achieved after 72 h. Administration of either prodrug, at doses which cause 6-8% body weight loss, 72 h after administration of the A5B7-CPG2 conjugate to the LoVo tumour-bearing mice resulted in tumour regressions and growth delays of 14-28 days. The ml? prodrug in combination with a high dose of conjugate (10mglkg-') gave the best anti-tumour activity despite being a 10-fold worse substrate for CPG2 than PGP. Prodrug alone, active drug alone or prodrug in combination with a non-specific conjugate had minimal anti-tumour activity in this tumour model.
Antibody-directed enzyme prodrug therapy (ADEPT) has been developed as an antibody-based targeting strategy for the treatment of cancer (Bagshawe, 1987; Bagshawe et al., 1988; Senter et al., 1988; Deonarain and Epenetos, 1994) .
The first step involves the administration of a tumourselective antibody linked to an enzyme. Following tumour loclisation of the conjugate and clearance of conjugate from blood and normal tissues, the second step involves administration of an inactive prodrug which is converted by the targeted enzyme at the tumour site into a potent cytotoxic drug. ADEPT has a number of potential advantages over other forms of antibody-based targeted therapy. Each enzyme molecule can potentially convert a large number of prodrug molecules into drug molecules at the tumour site. Potency limitations of directly targeting a cytotoxic drug molecule to a tumour with an antibody caused by the fact that only a limited number of drug molecules can be directly attached to an antibody without compromising tumour targeting (Thorpe, 1985) are thus overcome by ADEPT. A second advantage is that a small molecular weight cytotoxic drug is generated locally at the tumour site and outside the cell. The drug should be capable of diffiusion to reach tumour cells not directly targeted by the conjugate either owing to antigenic heterogeneity (Woodruff, 1983) or because the high molecular weight conjugate has failed to diffuse away from the tumour vasculature and reach tumour cells distant from the blood supply (Jain, 1989) .
We have previously reported on an ADEPT system which utilises the bacterial enzyme carboxypeptidase G2 (CPG2) (Bagshawe et al., 1988; Springer et al., 1991a) . CPG2 has no known mammalian equivalent and catalyses the hydrolytic cleavage of reduced and non-reduced folates to pteroates and L-glutamate (Minton et al., 1983) . The amide bond in the glutamate derivatives of benzoic acid mustards are also cleaved by CPG2 to release the benzoic acid mustard drug. A series of studies has shown that the combination of these benzoic acid mustard-glutamate prodrugs and a conjugate of CPG2 linked to either the anti-$-hCG antibody, W14 (Bagshawe et al., 1988; Springer et al., 1991a) Bagshawe, 1993) .
Two potential limitations of these ADEPT systems incorporating benzoic acid mustard prodrug are firstly that the drugs generated are not very potent (Springer et al., 1991b; Blakey et al., 1993) and secondly that the drugs have relatively long chemical (60 min) (Springer et al., 199 lb) and biological (1.6 h) half-lives which potentially permit escape of the drug from the tumour site into the periphery resulting in enhanced non-specific toxicity.
In this paper we describe the evaluation of two new prodrugs which are cleaved by CPG2 to release a potent and highly reactive phenol mustard drug. When compared with the original benzoic acid mustard prodrugs described previously (Bagshawe et al., 1988 , Springer et al., 1991a Blakey et al., 1993) these prodrugs when used in combination with the F(ab%A5B7-CPG2 conjugate result in improved anti-tumour activity in a colorectal tumour xenograft model.
Matedak and methods
The prodrugs used in these studies are 4-tN,N-bis(2-chloroethyl)aminoJ-phenoxycarbonyl-L-glutamic acid (phenol glutamate prodrug; PGP) and (S)-2{NN4-[N,N-bis(2-chloroethyl)amino]-phenoxycarbonylJamino]-4-(5-tetrazoyl)butyric acid (phenol tetrazole prodrug; PTP). The structure of these prodrugs and the corresponding phenol drug are shown in Figure 1 . Their synthesis will be described elsewhere (RI 3TC (Sherwood et al., 1985) .
The LoVo colorectal tumour cell ne was obtained from the European Collection of Animal Cell Cultures (ECACC no. 87060101 ).
E;nzyme kinetics
The K. and k,. of the prodrugs for CPG2 was determined using a method based on the literature CPG2 assay method for methotrexate (Sherwood et al., 1985 studies) on at least 1 day after treatment. Body weight loss was generally maximal at days 2-3 and mice generally regained body weight by day 7 after treatment with prodrug.
Preliminary studies were carried out with groups of two mice to establish the approximate MTD thus minimising the number of animals required to obtain an accurate MTD. The toxicity of conjugate and either PGP or PTP prodrug in normal and tumour-bearing athymic nude mice were not significantly different.
Anti-twnour studies Groups of 8 -10 female athymic nude mice were injected s.c. with 1 x 10' LoVo tumour cells. When the tumours were 4 -5 mm in diameter F(ab')2A5B7-CPG2 conjugate ( diameter and had a calculated weight (assuming a density of 1.0) of approximately 0.2-0.3 g. The anti-tumour activity was compared with control groups given PBS instead of either conjugate or prodrug. Other groups of tumour-bearing mice received F(ab')2MOPC-CPG2 control conjugate followed by prodrug or they were given prodrug or phenol mustard drug alone at the same time as the prodrug was administered in the combination arm of the study. Toxicity was monitored throughout the studies by measuring body weight and monitoring the condition of the animals. Statistical significance of the anti-tumour effects was judged using the analysis of variance (one-way) test (Armitage and Berry. 1987) . The anti-tumour effects of the PGP and PIP prodrugs in LoVo tumour xenografts are shown in Figure 4a and b and summansed in Table III . Both the 500 U and 2000 U kg-' conjugate dose levels were evaluated in combination with a prodrug dose which represented half the MTD (Table HI) Anti-tmnour activity A prodrug dosing regimen of three doses hourly over a 2 h time period was selected since both the PGP and PTP prodrugs have relatively short biological half-lives in mice of 20-30 min (results not shown) and it was thought that this dosing regimen might optimise exposure of prodrug to enzyme at the tumour site. Two conjugate dose levels were evaluated (500 and 2000 U CPG2 kg-1 corresponding to approximately 2.5 and 10 mg kg-' of total protein). The dose of prodrug, in combination with these conjugate dose levels, that caused 15% body weight loss was established, and the results are shown in Table II . Based on body weight loss, the PGP prodrug was 7-to 8-fold more toxic than the PTP ' ) alone (-), phenol mustard drug (3 x 2mg kg-') alone (0) or PGP prodrug (3 x 25mgkg-') 3 days after either F(ab%kMOPC
PBS (0), PTP prodrug (3 x 175 mg kg-') alone (U), phenol mustard drug (3 x 2 mg kg-') alone (0) or PTP prodrug (3 x 102 mg kg-') 3 days after either F(ab})MOPC-CPG2 (0) or 2000U CPG2 kg-' F(ab')A5B7-CPG2 (0). If PGP or PTP were adminisred in the absence of conjugate or the active phenol mustard drug was administered (3 x 2mg kg-') at a dose which caused 7-8% body weight loss, growth delays of less than 5 days were seen (Figure 4) .
Similarly, if the F(ab%A5B7-CPG2 conjugate was replaed with a control F(ab)2MOPC-CPG2 conjugate which does not bind to LoVo cells, growth delays with either PGP or PTP were seen of leIs than 5 days (Figure 4) . The plasma enzyme levels of the F(ab%MOPC-CPG2 conjugate were the same as those with the specific F(ab)A5B7-CPG2 conjugate at the time of prodrug administration (72 h) in these therapy studies. Thus to achieve tumour regrssions and growth delays>5 days, the combination of both the specific conjugate and prodrug was required.
The major finding to emerge from these studies is that we have been able to develop two new prodrugs of a potent phenol mustar drug which in combination with an F(ab%A5B7-CPG2 conjugate result in pronounced antitumour activity in a colorectal tumour xenograft model. The enzyme used in this ADEPT system, CPG2, is a bacterial carboxypptidasewith specificity for cleavage of amie bonds with a C-terminal glutamic acid residue. Previously it has been demonstrated that CPG2 is capable of cleaving amide bonds in both methotrexate (Sherwood et al., 1985) and benzoic acid musard-glutamate prodrugs (Bagshawe et al., 1988; Springer et al., 1991a) . Surprisingly, both PGP and PIP are very good substrates for CPG2 despite the fact that they contain a carbamate linkage (Table I) .
The phenol mustard drug liberated from PGP andFTP by CPG2 is some 50-to 100-fold more potent than the benzoic acid mustard drug liberated from the CMDA prodrug (Springer et al., 1991b; Blakey et al., 1993) which is currently in chnical trials combination with the F(ab%A5B7-CPG2 conjugate (Bagshawe et al., , 1995 Bagshawe, 1993 (Springer et al., 1991b Previously, Wallace and Senter (1991) reported an ADEPT system which incorporated a different prodrug of the phenol mustard drug used in these studies. The prodrug wasp[NVNBis(2chothyl)aminonyl phosphate (POMP) and the enzyme used to cleave the phosphate residue to release the drug was alkaline phosphatase. In a lung tumour xenograft model (H2981) the combination of antibody-alkalne phosphatase conjugate and POMP rulted 10-to 15-day growth delays with little evidence of tumour regressions. The activity of this system was probablylimited by endogenous alkaline phosphatase causing conversion of prodrug to drug and so enhancing toxicity. Since CPG2 is a bacterial enzyme and no active drug has been detected following the administration of the CMDA prodrug to patients in the absence of conjugate (Bagshawe, 1993; Bagshawe et al., 1995 
